We aimed to establish MYCN and ALK droplet digital PCR for the routine assessment of copy number status from sequential neuroblastoma blood and bone marrow samples to assist risk stratification and detection of cancer progression via MYCN- or ALK-dependent tumor-promoting subpopulations. The gene discussed is MYCN; the disease is cancer.